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This editorial refers to ‘Management of antithrombotic
therapy in atrial fibrillation patients presenting with acute
coronary syndrome and/or undergoing percutaneous
coronary or valve interventions: a joint consensus docu-
ment of the European Society of Cardiology Working
Group on Thrombosis, European Heart Rhythm Associ-
ation (EHRA), European Association of Percutaneous
Cardiovascular Interventions (EAPCI) and European Asso-
ciation of Acute Cardiac Care (ACCA) endorsed by the
Heart Rhythm Society (HRS) and Asia-Pacific Heart
RhythmSociety (APHRS).’ byLip et al., on page 3155–3179.
In a series of clinical scenarios decision making on the most appropri-
ate treatments to be applied in an individual patient may become very
difficult, in view of the risk of treatment-related adverse events that
have to be balanced against the benefits that a specific medication
or intervention may offer.
When a clinician has to decide on use of antithrombotic drugs in
the setting of a patient affected by atrial fibrillation (AF) experiencing
an acute coronary syndrome (ACS), the difficult task is avoiding
thrombotic events (stroke prevention, recurrent cardiac ischaemia
in an ACS setting, stent thrombosis if one is implanted) against the
risk of haemorrhage when oral anticoagulant (OAC) is combined
with antiplatelet therapy. This is really challenging, like the navigation
between Scylla and Charybdis in the Strait of Messina, between
Calabria and Sicily in Italy.1
In a patient with AF the need to decide on antithrombotic therapy
is common in clinical practice, whereby according to current guide-
lines2 an indication for OACs can be present in over 80% of AF
patients; however, 30% of them having vascular disease and around
20% requiring a percutaneous cardiovascular intervention (PCI) at
some stage.3 On the other hand, previously undetected AF often
complicates an ACS in up to 20% of patients.4
Many physicians, with different specialities and professional
tasks get ‘involved’ in the management of a patient affected by AF
(Figure 1), looking at this patient from variable perspectives, with
need to coordinate decisions and actions with some of the collea-
gues, in a team-work that nowadays becomes necessary in order to
guarantee the highest levels of care. For all of these colleagues, deci-
sion making and patient management in the setting of patients with
AF and ACS or invasive cardiovascular interventions is particularly
demanding and complex.
The joint consensus document of the European Society of Cardi-
ology (ESC) Working Group on Thrombosis, European Heart
Rhythm Association, European Association of Percutaneous Cardio-
vascular Interventions, and European Association of Acute Cardiac
Care, endorsed by Heart Rhythm Society and Asia-Pacific Heart
Rhythm Society has been prepared with the aim to help decision
making in this complex setting, where more frequently than in
other settings cohort studies and registries contribute to generation
of recommendations, in view of relative paucity of randomized clin-
ical trials.3
Performing a PCI and managing appropriately the antithrombotic
regimen is a task with the typical characteristics of ‘complex interven-
tions’, in view of the multiple interacting components, the implica-
tions in terms of organization, of care, and the relevance and
variability of outcomes. Therefore, the European consensus docu-
ment has important implications in terms of organization of care
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and should be an important reference for organizing networks for
patient referral and patient follow-up, whereby interventional cardi-
ologists, clinical cardiologists, electrophysiologists, and all the other
physicians involved in the care of AF patients should coordinate
their work, in an attempt to obtain such synergistic effects that
these types of clinical scenarios may request.
In such situations, decision making has to be based on a compre-
hensive patient-centred and individualized approach5– 7 whereby
all the knowledge from scientific evidence, summarized in consensus
guidelines and consensus documents2,3 has to be combined with
individual clinical assessment, with the important aid of a series of
user-friendly risk scores that appropriately depict the individual
risk, in terms of stroke or bleeding hazards, as well as in terms of like-
lihood of appropriate anticoagulation use.8– 10
Individualization and personalization of care is actually needed,
both on the side of physicians taking care of medical therapy [antipla-
telet drugs, or OAC, whether non-vitamin K antagonist or vitamin K
antagonist (VKA)] and on the side of interventional cardiologists
(choice of access, choice of stent, etc), thus reaching an agreement
also on the optimal duration of combined antithrombotic treatment.
The European consensus document3 proposes a series of specific
concepts that carry important practical implications:
(1) Non-vitamin K antagonist OACs (NOACs) and VKA can be used
when an OAC is recommended;
(2) If a VKA is used in combination with antiplatelet agents, inter-
national normalized ratio (INR) should ideally be controlled
between 2.0 and 2.5, with a good time in therapeutic range
(.70%, which may be difficult to achieve);
(3) If a NOAC is used in combination with antiplatelet agents, the
respective lower tested dose (dabigatran 110 mg twice a day,
rivaroxaban 15 mg once a day, apixaban 2.5 mg twice a day)
should be used;
(4) New generation P2Y12-inhibitors (prasugrel, ticagrelor) should
not be used in antithrombotic combination therapy with anticoa-
gulants before specific studies validate their role in combined
therapy.
Figure 2, from the Consensus document,3 shows how to reach a final
decision on the most appropriate antithrombotic treatment, as a
result of a multi-staged approach that considers stroke risk, bleeding
risk, clinical setting (ACS or stable coronary artery disease) and type
of intervention performed (using drug-eluting stent or bare-metal
stent), with different potential choices according to needed intensity
of antithrombotic therapy and time horizon (triple or dual therapy
including oral anticoagulants, dual antiplatelet therapy, oral anticoa-
gulants alone).3 Where VKA is used, good quality INR control is
necessary, aiming for a time in therapeutic range .70%.11,12
As the document reports, many areas of uncertainty remain and
current recommendations are based on expert consensus and/or
derived from extrapolation of data from patients in sinus rhythm,
observational studies, subgroup analyses, and a few smaller con-
trolled trials. This is particularly the case of the NOACs, for which
there is growing interest but limited evidence available, until the com-
pletion of ongoing trials. This is, particularly, the case given the poten-
tial for increased gastrointestinal bleeds with some NOACs,
probably accentuated when the NOAC is combined with an antipla-
telet drug.13
The best therapeutic solution, considering the competing risks of
ischaemic stroke, bleeding, recurrent coronary events, and stent
thrombosis surely requires some degree of personalized manage-
ment, which could substantially benefit from a team work among
all the actors involved.5– 7
In these complex settings, it is quite important to have ‘reality
check’ of what happens in ‘real world’ clinical practice. The Euro
Observational Research Programme Atrial Fibrillation (EORP-AF)
Pilot Registry, promoted by the European Society of Cardiology,
offers the possibility to evaluate the full contemporary picture of
AF patients across Europe and of antithrombotics use, according to
current guidelines.2 The EORP-Pilot phase collected information,
on all patients presenting to cardiologists as in- or out-patients
with an electrocardiogram documented diagnosis of AF in the year
prior to enrolment, and 3119 patients were collected from February
2012 to March 2013. Among these patients, enrolled in nine ESC
member Countries, a history of coronary artery disease was
present in around 48% of patients, without significant regional differ-
ences.14 Coronary artery disease was associated with a significantly
reduced use of OACalone,15 lowerprescription of NOACs anda sig-
nificantly increased prescriptionof antiplatelet drugs aloneor in com-
bination with OAC.
According to these data, coming from ‘real world’ clinical practice,
it is clear that coronary artery disease, in general, markedly affects
prescription and management of antithrombotic treatment in AF
patients, despite the potential for high bleeding.16,17 It is expected
that when the natural history of coronary artery disease evolves to
an acute phase, i.e. an ACS, with need for new treatments and
PCIs, the difficulty of decision making in such a complex and challen-
ging scenariowill be magnified. For these reasons, we think that all the
cardiologists and particularly the electrophysiologists taking care of
AF patients will benefit from the availability of these updated, clinic-
ally oriented recommendations.3 In this evolving scenario growing
interest is developing on NOACs, whose uptake in AF patients is in-
creasing, but with need for more data on the specific setting of ACS,
some trials are ongoing.3
As for all the medical or interventional treatments with high impact
on practices, organization of care and costs, the implications and con-
sequences of recommended strategies should be object of analysis
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Figure 1 Physicians, with different specialities and professional
tasks that manage a patient affected by atrial fibrillation (AF).
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and re-evaluation, in accordance with the path of Health Technology
Assessments.18 National and international registries or other tar-
geted initiatives will be of help to give the appropriate feedback to
clinicians, regulators and policy-makers.
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